Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tumor 'flare' hypercalcemia--an additional indication for bisphosphonates?

Z Nikolic-Tomasević1, S Jelic, I Popov

  • 1Institute for Oncology and Radiology of Serbia, Belgrade, Yugoslavia. jelics@ncrc.ac.yu

Oncology
|March 13, 2001
PubMed
Summary

Hypercalcemia flare during tamoxifen treatment for breast cancer can be effectively managed with bisphosphonates. This treatment allows patients to safely continue tamoxifen therapy, preventing premature discontinuation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spin crossover in metal-organic frameworks: A crystal embedded multi-reference study.

The Journal of chemical physics·2025
Same author

Use of Corneal Topography in Pediatric Ophthalmology.

Ceska a slovenska oftalmologie : casopis Ceske oftalmologicke spolecnosti a Slovenske oftalmologicke spolecnosti·2023
Same author

CHANGE OF SURGICALLY INDUCED CORNEAL ASTIGMATISM AND POSITION OF ARTIFICIAL INTRAOCULAR LENS OVER TIME.

Ceska a slovenska oftalmologie : casopis Ceske oftalmologicke spolecnosti a Slovenske oftalmologicke spolecnosti·2023
Same author

SARS-COV-2 PANDEMIC FROM THE OPHTHALMOLOGIST`S PERSPECTIVE. A REVIEW.

Ceska a slovenska oftalmologie : casopis Ceske oftalmologicke spolecnosti a Slovenske oftalmologicke spolecnosti·2022
Same author

ENDOTHELIAL CELL LOSS AFTER PARS PLANA VITRECTOMY.

Ceska a slovenska oftalmologie : casopis Ceske oftalmologicke spolecnosti a Slovenske oftalmologicke spolecnosti·2021
Same author

PUPILLOTONIA AND ADIE SYNDROME.

Ceska a slovenska oftalmologie : casopis Ceske oftalmologicke spolecnosti a Slovenske oftalmologicke spolecnosti·2021

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Background:

  • Tamoxifen treatment for breast cancer can cause a rare but serious side effect known as hypercalcemia flare.
  • This potentially life-threatening condition occurs in 4-5% of patients with bone metastases, typically early in treatment.
  • Current management guidelines lack specific recommendations beyond tamoxifen withdrawal.

Observation:

  • A 7-year study observed 87 hypercalcemic patients with metastatic breast cancer, identifying 10 cases of tamoxifen-induced hypercalcemia.
  • Flare hypercalcemia was diagnosed based on normal pre-treatment calcium levels and onset within 6 weeks of hormonal therapy initiation.
  • The median time to onset was 14 days, median duration 8.5 days, with a median calcium level of 3.09 mmol/l.

Findings:

Related Experiment Videos

  • All 10 patients received hydration; 7 with calcium >3.0 mmol/l were treated with disodium pamidronate (30-90 mg/24 h).
  • Normocalcemia was achieved in all patients, enabling continued tamoxifen treatment without hypercalcemia recurrence.
  • Median survival for these patients was 177 days.

    • Implications:

    • Bisphosphonate use in flare hypercalcemia may permit safe tamoxifen re-administration, avoiding premature treatment cessation.
    • Flare hypercalcemia could be an additional indication for bisphosphonate therapy in oncology.
    • This strategy potentially improves treatment adherence and patient outcomes in metastatic breast cancer.